Verrica Pharmaceuticals

Aging Global Population And Patient-Friendly Solutions Will Expand Dermatology Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

14 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$20.00

70.2% undervalued

21 Aug

US$5.97

-75.7%

-1.3%

-75.7%

-1.3%

Author's Valuation

US$20.0

70.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$20.0

70.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

46.13%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$52.35m

Earnings '28

9.65x

PE Ratio '28

US$505.26m

Market Cap '28

US$505.26m

Market Cap '28

20.75m

No. shares '28

US$24.35

Share Price '28

US$24.35 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$20.00

Fair Value '25